CorMedix Inc. (CRMD) Stock

CorMedix Inc. (CRMD) is a Healthcare stock trading at $8.65 (as of 2026-06-18), with a market capitalization of $662.13M and a trailing P/E of 4.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CorMedix Inc. is a biopharmaceutical company developing and commercializing therapeutic products for preventing and treating infectious and inflammatory diseases in the United States and internationally. Its lead candidate, DefenCath/Neutrolin, is an anti-infective solution intended to reduce and prevent catheter-related infections and thrombosis for patients using central venous catheters in settings such as hemodialysis, total parenteral nutrition, and oncology.

Valuation — source: SEC EDGAR (first-party)
Price	$8.65
Market Cap	$662.13M
P/E Ratio	4.0
EV / EBITDA	2.5
Price / Book	1.57
Price / Sales	1.71
DCF Value (model)	$39.06
DCF Upside vs Price	351.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$311.71M
Net Margin	52.3%
Return on Equity	41.4%
Current Ratio	2.98
Revenue Growth (YoY)	226.1%
EPS Growth (YoY)	50.0%
FCF Growth (YoY)	111.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.93 (grey)

Valuation vs Sector & Industry
Stock P/E	4.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-80.8%
vs Industry	-76.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($52.32M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Joseph Todisco
Employees	64
Country	US
IPO Date	2010-05-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.